HighTide Therapeutics Future Growth
Future criteria checks 0/6
HighTide Therapeutics's EPS is expected to grow by 66% per annum.
Key information
n/a
Earnings growth rate
66.0%
EPS growth rate
Biotechs earnings growth | 35.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 19 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,000 | N/A | N/A | N/A | 1 |
12/31/2023 | N/A | -939 | -359 | -358 | N/A |
9/30/2023 | N/A | -803 | -300 | -300 | N/A |
6/30/2023 | N/A | -666 | -242 | -242 | N/A |
3/31/2023 | N/A | -428 | -207 | -207 | N/A |
12/31/2022 | N/A | -190 | -173 | -172 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2511's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if 2511's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2511's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2511's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2511's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2511's Return on Equity is forecast to be high in 3 years time